↓ Skip to main content

Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial

Overview of attention for article published in BMC Cancer, July 2012
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age

Mentioned by

twitter
1 tweeter
facebook
1 Facebook page

Citations

dimensions_citation
128 Dimensions

Readers on

mendeley
125 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial
Published in
BMC Cancer, July 2012
DOI 10.1186/1471-2407-12-305
Pubmed ID
Authors

David A Palma, Cornelis J A Haasbeek, George B Rodrigues, Max Dahele, Michael Lock, Brian Yaremko, Robert Olson, Mitchell Liu, Jason Panarotto, GwendolynHMJ Griffioen, Stewart Gaede, Ben Slotman, Suresh Senan

Abstract

Stereotactic ablative radiotherapy (SABR) has emerged as a new treatment option for patients with oligometastatic disease. SABR delivers precise, high-dose, hypofractionated radiotherapy, and achieves excellent rates of local control. Survival outcomes for patients with oligometastatic disease treated with SABR appear promising, but conclusions are limited by patient selection, and the lack of adequate controls in most studies. The goal of this multicenter randomized phase II trial is to assess the impact of a comprehensive oligometastatic SABR treatment program on overall survival and quality of life in patients with up to 5 metastatic cancer lesions, compared to patients who receive standard of care treatment alone.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 125 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 2%
Spain 1 <1%
Belgium 1 <1%
Unknown 121 97%

Demographic breakdown

Readers by professional status Count As %
Researcher 18 14%
Other 18 14%
Student > Ph. D. Student 13 10%
Student > Master 12 10%
Student > Bachelor 10 8%
Other 32 26%
Unknown 22 18%
Readers by discipline Count As %
Medicine and Dentistry 68 54%
Physics and Astronomy 8 6%
Nursing and Health Professions 6 5%
Agricultural and Biological Sciences 3 2%
Biochemistry, Genetics and Molecular Biology 3 2%
Other 7 6%
Unknown 30 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2018.
All research outputs
#8,387,885
of 13,441,462 outputs
Outputs from BMC Cancer
#2,441
of 5,055 outputs
Outputs of similar age
#142,211
of 279,002 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 13,441,462 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,055 research outputs from this source. They receive a mean Attention Score of 4.0. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,002 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them